Released May 6, 2020, after the close
10-Q filed May 8, 2020, 38 days after period end · 0001299130-20-000035
Q1 2020 · 10-Q
Revenue$15.60M$15.60M −5.0% vs Q1 2019−44.2% vs Q4 2019
Net Income$1.26M$1.26M N/M vs Q1 2019N/M vs Q4 2019
EPS Diluted$0.01$0.01 N/M vs Q1 2019no prior Q4 2019 on file
Gross Profit$7,488,000+46.3%
Operating Income-$32,709,000N/M
Operating Cash Flow$75,363,000N/M
Free Cash Flowderived$75,246,000N/M
Margins · derived
Gross margin48.0%+16.9 pt vs Q1 2019
Operating margin-209.7%−26.2 pt vs Q1 2019
Net margin8.1%+192.7 pt vs Q1 2019
What the release said
The release
Same quarter
| Metric | Q1 2020 | Q1 2019 | Q1 2018 | Q1 2017 |
|---|---|---|---|---|
| Revenue | $15.60M | $16.43M | $19.36M | $24.92M |
| Net Income | $1.26M | -$30.32M | -$24.18M | -$23.87M |
| EPS Diluted | $0.01 | -$0.20 | -$0.20 | -$0.26 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pacific Biosciences of California, Inc. · CIK 1299130 · Engraved from SEC EDGAR